REVANCE THERAPEUTICS INC (RVNC) Fundamental Analysis & Valuation
NASDAQ:RVNC • US7613301099
Current stock price
3.65 USD
+0.01 (+0.27%)
At close:
3.66 USD
+0.01 (+0.27%)
After Hours:
This RVNC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. RVNC Profitability Analysis
1.1 Basic Checks
- RVNC had negative earnings in the past year.
- In the past year RVNC has reported a negative cash flow from operations.
- RVNC had negative earnings in each of the past 5 years.
- In the past 5 years RVNC always reported negative operating cash flow.
1.2 Ratios
- RVNC has a Return On Assets (-39.96%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.96% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- RVNC's Gross Margin of 72.61% is fine compared to the rest of the industry. RVNC outperforms 79.57% of its industry peers.
- RVNC's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for RVNC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.61% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
2. RVNC Health Analysis
2.1 Basic Checks
- RVNC does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, RVNC has more shares outstanding
- Compared to 1 year ago, RVNC has a worse debt to assets ratio.
2.2 Solvency
- RVNC has an Altman-Z score of -6.34. This is a bad value and indicates that RVNC is not financially healthy and even has some risk of bankruptcy.
- RVNC has a worse Altman-Z score (-6.34) than 67.20% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.34 |
ROIC/WACCN/A
WACC8.5%
2.3 Liquidity
- RVNC has a Current Ratio of 4.12. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.
- RVNC has a Current ratio (4.12) which is comparable to the rest of the industry.
- RVNC has a Quick Ratio of 3.05. This indicates that RVNC is financially healthy and has no problem in meeting its short term obligations.
- The Quick ratio of RVNC (3.05) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.05 |
3. RVNC Growth Analysis
3.1 Past
- RVNC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 53.16%, which is quite impressive.
- RVNC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.34%.
- Measured over the past years, RVNC shows a very strong growth in Revenue. The Revenue has been growing by 129.20% on average per year.
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
3.2 Future
- The Earnings Per Share is expected to grow by 18.17% on average over the next years. This is quite good.
- RVNC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 22.31% yearly.
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%
3.3 Evolution
- The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. RVNC Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for RVNC. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RVNC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as RVNC's earnings are expected to grow with 22.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.61%
EPS Next 3Y22.8%
5. RVNC Dividend Analysis
5.1 Amount
- No dividends for RVNC!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RVNC Fundamentals: All Metrics, Ratios and Statistics
3.65
+0.01 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-04 2025-03-04/amc
Inst Owners72.87%
Inst Owner Change0%
Ins Owners1.85%
Ins Owner Change0%
Market Cap381.02M
Revenue(TTM)247.00M
Net Income(TTM)-184.44M
Analysts70.67
Price Target5.25 (43.84%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.02%
Min EPS beat(2)4.62%
Max EPS beat(2)33.41%
EPS beat(4)4
Avg EPS beat(4)19.57%
Min EPS beat(4)4.62%
Max EPS beat(4)33.41%
EPS beat(8)5
Avg EPS beat(8)-1.49%
EPS beat(12)6
Avg EPS beat(12)-3.54%
EPS beat(16)10
Avg EPS beat(16)-1.96%
Revenue beat(2)0
Avg Revenue beat(2)-8.84%
Min Revenue beat(2)-14.73%
Max Revenue beat(2)-2.96%
Revenue beat(4)1
Avg Revenue beat(4)-4.4%
Min Revenue beat(4)-14.73%
Max Revenue beat(4)10.16%
Revenue beat(8)3
Avg Revenue beat(8)-2.2%
Revenue beat(12)6
Avg Revenue beat(12)-0.84%
Revenue beat(16)9
Avg Revenue beat(16)2.98%
PT rev (1m)-31.93%
PT rev (3m)-42.51%
EPS NQ rev (1m)-18.27%
EPS NQ rev (3m)-57.56%
EPS NY rev (1m)0%
EPS NY rev (3m)-13.24%
Revenue NQ rev (1m)6.51%
Revenue NQ rev (3m)-13.71%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-7.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.93
EYN/A
EPS(NY)-1.11
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.83
OCFYN/A
SpS2.37
BVpS-1.56
TBVpS-1.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.96% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.61% | ||
| FCFM | N/A |
ROA(3y)-60.64%
ROA(5y)-53.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5YN/A
F-Score3
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 106.69% | ||
| Cap/Sales | 1.63% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.12 | ||
| Quick Ratio | 3.05 | ||
| Altman-Z | -6.34 |
F-Score3
WACC8.5%
ROIC/WACCN/A
Cap/Depr(3y)40.78%
Cap/Depr(5y)54.97%
Cap/Sales(3y)6.23%
Cap/Sales(5y)171.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.3%
EPS Next Y57.03%
EPS Next 2Y30.61%
EPS Next 3Y22.8%
EPS Next 5Y18.17%
Revenue 1Y (TTM)15.34%
Revenue growth 3Y148.24%
Revenue growth 5Y129.2%
Sales Q2Q%5.47%
Revenue Next Year12.8%
Revenue Next 2Y19.79%
Revenue Next 3Y22.43%
Revenue Next 5Y22.31%
EBIT growth 1Y31.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.87%
EBIT Next 3Y26.12%
EBIT Next 5Y20.68%
FCF growth 1Y9.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.22%
OCF growth 3YN/A
OCF growth 5YN/A
REVANCE THERAPEUTICS INC / RVNC Fundamental Analysis FAQ
What is the fundamental rating for RVNC stock?
ChartMill assigns a fundamental rating of 2 / 10 to RVNC.
What is the valuation status for RVNC stock?
ChartMill assigns a valuation rating of 1 / 10 to REVANCE THERAPEUTICS INC (RVNC). This can be considered as Overvalued.
Can you provide the profitability details for REVANCE THERAPEUTICS INC?
REVANCE THERAPEUTICS INC (RVNC) has a profitability rating of 1 / 10.
What is the financial health of REVANCE THERAPEUTICS INC (RVNC) stock?
The financial health rating of REVANCE THERAPEUTICS INC (RVNC) is 2 / 10.
What is the earnings growth outlook for REVANCE THERAPEUTICS INC?
The Earnings per Share (EPS) of REVANCE THERAPEUTICS INC (RVNC) is expected to grow by 57.03% in the next year.